The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

FDA expands approval of Seattle Genetics? Adcetris for advanced classical Hodgkin Lymphoma.....           Cipher to buy Cardiome Pharma's Canadian business portfolio.....           GSK begins phase III trial of Benlysta, rituximab combo in systemic lupus erythematosus.....           Prothena, Celgene collaborate to develop new therapies for neurodegenerative diseases.....           In a boon for Roche, Novartis and more, Chinese Premier plans 'zero tariff' on imported cancer drugs.....           Trump, Azar say a plan for drug prices is coming in 'about a month'.....           Incyte hikes CEO Hoppenot?s pay 36%?to $16M?despite its R&D setbacks.....           Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?.....           AstraZeneca owes $192M in royalties from massive Merck deal, selumetinib licensor Array argues.....           AbbVie chief racks up $22.6M in 2017 pay, complete with $600K in personal jet use.....           Heron?s pain drug succeeds in phase 3 bunionectomy and hernia repair trials.....           FDA grants Xtandi priority review for Nonmetastatic CRPC.....           Arena?s etrasimod meets primary and secondary endpoints in ulcerative colitis trial.....           Study says non-antibiotic drugs affect gut bacteria.....           GlaxoSmithKline's Shingrix launch gets a jump-start with CVS move to stock thousands of pharmacies.....           GlaxoSmithKline scores retail deal with CVS, spreading Shingrix to thousands of pharmacies.....           Brineura, Kymriah come up big as #FierceMadness field narrows to 32.....           Feds charge 5 doctors over role in alleged Insys bribery scheme.....           Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study.....           Lundbeck to buy Prexton Therapeutics in EUR905m deal.....           FDA approves Hizentra to treat chronic inflammatory demyelinating polyneuropathy.....           Bavarian Nordic partners with US DoD to develop vaccine for encephalitis virus.....           FiercePharmaAsia?China?s new drug regulator, Teva?s Celltrion headache, NextCODE-Google tie-up.....           Citing risk of 'serious consequences,' Bayer pulls Alka-Seltzer boxes listing incorrect ingredients.....           Pfizer hands CEO massive pay raise?plus $8M bonus?to dissuade him from retiring.....           New Hikma CEO Olafsson gets to work on 200 more generics layoffs.....           Merck's Keytruda shows up its rivals with NICE backing in bladder cancer.....           Ionis licenses to Akcea global rights to inotersen in $1.7bn deal.....           Destiny Pharma's XF-73 MRSA drug gets FDA fast track designation.....           Zymeworks plans to take second drug into trials in HER2-expressing cancers.....           Alexion?s rare blood disorder treatment ALXN121 succeeds in phase 3 study.....           Celltrion's manufacturing headache likely to delay Teva migraine drug until 2019: analysts.....           Big Pharma's winners and losers last year? AbbVie and AstraZeneca up, GSK down.....           Forget that 'no breakup' vow. Allergan's CEO now says a strategic review is happening.....           With U.S. brand sales deflating, Pfizer gears up for over-the-counter Viagra in U.K......           GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm.....           FDA puts clinical hold on Solid Biosciences' Duchenne gene therapy trial.....           Proteostasis' PTI-428 gets FDA orphan drug designation to treat cystic fibrosis.....           CrownBio selected to advance Phanes Therapeutics' oncology drug pipeline.....           Foghorn Therapeutics raises $50m in funding.....           Stand Up to Cancer executives talk celebrities, partnerships and research for pharma marketers.....           FDA grants priority review to Merck?s Keytruda for cervical cancer.....           Takeda looks east for another Entyvio growth spurt.....           Allergan CEO Saunders grabs $32.8M in 2017 pay despite tribal licensing debacle.....           #FierceMadness gets serious with 64 drug names, including play-in victors Taltz, Nerlynx.....           Oregon, the latest state to tackle high drug prices, pushes through transparency law.....           FDA grants Merck?s Keytruda priority review for cervical cancer.....           Kiadis raises €23.4m to develop immunotherapy for GVHD.....           AbbVie?s Elagolix succeeds in second phase 3 uterine fibroid study.....           Practical magic: Google counsels pharma to create 'seamless' digital experiences.....           FDA's promo police put pharma marketing to the test with 6 new research studies.....           Here's a DTC shocker: Pharma ad spend actually fell in 2017 for first time in years, Kantar says.....           After a rough season, FDA chief Gottlieb says 'holy grail' flu shot is years off.....           China creates new drug regulator in biggest government overhaul in years.....           ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%.....           Former GSK chief and pricing critic Witty steps in as Optum CEO.....           Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar.....           FDA sends Hikma back to the clinic with generic Advair.....           Biogen to acquire Pfizer?s schizophrenia drug for up to $590m.....           Janssen?s Invokana reduces cardiovascular risk in diabetes patients.....           Sarepta plans to submit NDA for Golodirsen Duchenne drug by year end.....           FDA upholds decision on generic version of GSK?s asthma/COPD inhaler Advair Diskus.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

We are re-running the Developability Workshop and Regulatory Essentials training events which have proved enormously popular when run before.

In March, we have the first one of our collaborative meetings, 'Emerging technologies in therapeutic oligonucleotides', hosted by MedImmune, followed by 'APS Current Regulatory trends and updates in parenteral drug product development' that will be informative and interactive describing the current regulatory requirements, especially focusing on recent changes in guidelines, as well as covering topical issues, trends and developments in the wider field of parenteral products.

Don’t forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

Emerging technologies in therapeutic oligonucleotides
13 March 2018 - MedImmune, Cambridge
MedImmune, AstraZeneca and GE Healthcare Life Sciences, in partnership with GSK, Roche, University of Oxford, BioMax and Academy of Pharmaceutical Sciences are pleased to invite you to their sixth oligonucleotide networking event.
To learn more and to register, click here

APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018 - Burleigh Court, Loughborough University
This residential course is aimed at pharmaceutical scientists and regulatory affairs professionals involved in the development, manufacture, control or registration of parenteral products. Speakers will include key industry and MHRA experts.
To learn more and to register, click here

APS Industrial Insights
26 - 27 March 2018 - Pfizer / Mylan at Discovery Park, Sandwich
EarlyBird deadline extended to midnight on Monday 5 March... register now!
An event for undergraduate and postgraduate students interested in exploring opportunities in the Pharmaceutical Industry, through a series of talks by pharmaceutical scientists working within the industry as well as a tour of the Pfizer Research and Development facilities.
To learn more and to register, click here

Accelerating paediatric formulation development
Presentation of output from SPaeDD-UK Project

28 March 2018 - Friends House, London
The Smart Paediatric Drug Development (SPaeDD) initiative co-funded by Innovate UK (the UK’s Innovation Agency) is a cross company and academic centre initiative to accelerate paediatric formulation development. The collaboration has now reached the end of its funding period and this meeting will present the final outputs from the project work streams. Each of these has produced outputs which will no doubt significantly assist the way in which medicines are developed and tested for children.
To learn more and to register, click here

APS Developability Workshop
10 - 11 April 2018 - Granta Park, Cambridge
Learn from a pharmaceutics and biopharmaceutics perspective what is required to assess a molecule in discovery and its suitability for ‘candidate selection’; determine how ‘developable’ it is with associated risk, time and cost implications; and what is needed to progress it through pre-clinical studies and into Phase 1 and 2a clinical studies to achieve Proof of Concept.
To learn more and to register, click here

APS Regulatory Essentials II
22—23 May 2018 - Burleigh Court, Loughborough University
This is a residential course aimed at pharmaceutical scientists and regulatory/quality professionals in originator and generics’ companies who will benefit from gaining a better appreciation of key elements in the development and registration of oral dosage forms.
To learn more and to register, click here

7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop
Nanomedicine drug delivery: Opportunities and Challenges
OrBiTo (Innovative Tools for Oral Biopharmaceutics) Conference


Reflections on APS PharmSci 2017 Conference

Date: 5 - 7 September 2017
Location: De Havilland Campus, University of Hertfordshire, Hatfield
Conference Chair: Professor Abdul Basit (University College London)
Theme: Pharmaceutical Science without Borders

A very successful 3-day conference provided an excellent interactive face to face forum for exchange of knowledge and sharing learnings and experiences in many aspects of the pharmaceutical sciences. With 80+ inspiring speakers and over 390 delegates joined together from academia, the Pharmaceutical Industry, and service companies. During the sessions, there was a steady flow of discussion which continued into the breaks and around the exhibition stands and posters.

Young pharmaceutical scientists had their first opportunity to present either a poster or podium presentation (or indeed both!) which is a major strength of APS PharmSci.


Read more, as Linda Hakes (Retiring APS Chair) and Mark McAllister (APS Chair) talk about their experiences at this year’s PharmSci.

Follow us
Upcoming Events
APS Industrial Insights 2018
26 - 27 March 2018
Accelerating paediatric formulation development
Presentation of output from SPaeDD-UK Project

28 March 2018
APS Developability Workshop
10 - 11 April 2018
APS Regulatory Essentials II
22 - 23 May 2018
APS Nanomedicines for the Delivery of Biologics
18 July 2018
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.